Ultragenyx Pharmaceutical (RARE) vs First Tracks Biotherapeutics (TRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
First Tracks Biotherapeutics is the larger company by market cap ($1.75 billion vs $1.68 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RARE | TRAX |
|---|---|---|
| Share price | $16.48 | $41.64 |
| Market cap | $1.68B | $1.75B |
| 1-day change | -4.30% | -6.34% |
| YTD return | -28.35% | — |
| 1-year return | -50.94% | — |
| 5-year return | -78.45% | — |
| Forward P/E | 11.50 | — |
| EPS (TTM) | $-5.17 | $-4.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $673.00M | — |
| Revenue growth (YoY) | +20.18% | — |
| Net income (latest FY) | $-575.00M | — |
| Operating margin | -79.49% | — |
| Net margin | -85.44% | — |
| 52-week high | $39.89 | $54.78 |
| 52-week low | $12.73 | $14.72 |
| Distance from 52-week high | -58.69% | -23.99% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +50.49% | +80.52% |
| Average volume | 4.69M | 826.70K |
| Shares outstanding | 101.92M | 42.02M |
| Employees | 1,371 | 104 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
About First Tracks Biotherapeutics
TRAX stock →First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees
RARE vs TRAX FAQ
Which is bigger, Ultragenyx Pharmaceutical or First Tracks Biotherapeutics?
First Tracks Biotherapeutics (TRAX) is larger, with a market capitalization of $1.75B compared with $1.68B for Ultragenyx Pharmaceutical (RARE).
Are Ultragenyx Pharmaceutical and First Tracks Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.